Yes, tirzepatide has been shown to significantly reduce appetite and energy intake, contributing to weight loss in individuals with type 2 diabetes
Our peer-reviewed study in JMIR Formative Research found that active subscribers on the semaglutide-supported programme lost an average of 19.1% of their body weight at 12 months, with 77.7% achieving at least 10% weight loss
The nutrient gap: Reduced food intake can result in an insufficient intake of essential vitamins and minerals
Klinic pairs you with skilled healthcare providers to determine if Zepbound is right for you, while managing insurance and prior authorizations, letting you focus more on your health and less on administrative tasks
Going forward, follow safe guidelines and monitor your body's responses
Avoid excessive sun exposure, especially during peak UV hours (10 a.m